Acquisition by James Stanker of 2307 shares of Processa Pharmaceuticals subject to Rule 16b-3
PCSA Stock | USD 0.23 0.02 9.52% |
About 55% of Processa Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Processa Pharmaceuticals stock suggests that some investors are interested at this time. The current market sentiment, together with Processa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Processa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Filed transaction by Processa Pharmaceuticals Officer Chief Financial Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Processa Pharmaceuticals Fundamental Analysis
We analyze Processa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Processa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Processa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Processa Pharmaceuticals is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Processa Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Processa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Processa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Processa Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Processa Pharmaceuticals Related Equities
TPCS | TechPrecision Common | 16.42 | ||||
FENC | Fennec Pharmaceuticals | 6.12 | ||||
SNTI | Senti Biosciences | 3.57 | ||||
IMNM | Immunome | 3.40 | ||||
GANX | Gain Therapeutics | 2.08 | ||||
LIXT | Lixte Biotechnology | 0.21 | ||||
MNPR | Monopar Therapeutics | 5.75 |
Complementary Tools for Processa Stock analysis
When running Processa Pharmaceuticals' price analysis, check to measure Processa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Processa Pharmaceuticals is operating at the current time. Most of Processa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Processa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Processa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Processa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |